Primary Sclerosing Cholangitis clinical trials at UCSF
1 research study open to eligible people
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
open to eligible people ages 18-75
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
San Francisco, California and other locations